Breathe Me

Vapotherm to Report Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 26, 2022
Health, Medical Supplies, Other Health, Medical Devices, U.S. Securities and Exchange Commission, Breathe Me, Telephone, Investor relations, Regulation Fair Disclosure, Investor, NYSE, Patient, Security (finance), Company, VAPO, Hypercapnia, Hypoxemia, Gas, Regulation, Pharmaceutical industry, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 90 days following completion of the call.

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Optical, General Health, Health, FDA, Clinical Trials, Other Health, Pressure, Physician, LinkedIn, Spasm, Fibroblast, Breathe Me, Disease, Medicine, Diabetes, Nausea, Fatigue, Menstrual disorder, Graves' ophthalmopathy, Science, TED, Inflammatory bowel disease, Myalgia, FACP, Patient, Diarrhea, Courage, Tachycardia, Research, Twitter, Instagram, Cell, Blood pressure, Severe cognitive impairment, Hair, Nasdaq, Red, Grit, Hyperglycemia, Autoantibody, ATA, Headache, Swelling, Pain, Incidence, IBD, European Group, Lists of World Heritage Sites, Autoimmunity, Inflammation, Health, FDA, Exophthalmos, Huber loss, American Thyroid Association, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Birth control, Facebook, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.
  • We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.
  • Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.
  • Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD).

Spiders, Snakes and Other Spooky Pet Poison Dangers

Retrieved on: 
Wednesday, October 12, 2022
Myalgia, Veterinarian, Spider, Cramp, Color, Latrodectus, Bleeding, Bird, Biting, Animal, Circulatory collapse, Family, Bitten, Diarrhea, Pharmacy, IV, Medicine, Mouth, Xylitol, Veterinary medicine, Google, Dog, PETS, Seizure, Blood pressure, Extrapyramidal system, Eye, DVM, Candy, Poisoning, Vomiting, Black widow, Cat, GiFT, Chocolate, Spider bite, Diazepam, Swelling, DABT, Snake, Poison, Wiley, Breathe Me, Noise, Obstruction, Stomach, Paralysis, Bruise, Methocarbamol, Death, Coffee, Spasm, Tremor, Human, Toxicology, Flaccid paralysis, Fireworks, Medical imaging, Halloween

MINNEAPOLIS, Oct. 12, 2022 /PRNewswire/ -- Halloween conjures up many images, including spiders, snakes, ghosts and, for many revelers, buckets of candy. Most pet lovers know not to give their animals chocolate, but spiders and snakes can also pose a real danger to pets. As families celebrate this frightening haunted holiday, the toxicology experts at Pet Poison Helpline want to warn pet lovers about other real scares like spiders and snakes that can seriously sicken or kill your pet in this month's installment of Toxin Tails.

Key Points: 
  • As families celebrate this frightening haunted holiday, the toxicology experts at Pet Poison Helpline want to warn pet lovers about other real scares like spiders and snakes that can seriously sicken or kill your pet in this month's installment of Toxin Tails.
  • Being a trusted source for pet toxicology advice, Pet Poison Helpline is highly recommended by human poison control centers and veterinary professionals.
  • Pet Poison Helpline created Toxin Tails to educate the veterinary community and pet lovers on the many types of poisoning dangers facing pets, both in and out of the home.
  • As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $75 per incident includes follow-up consultations for the duration of the case.

Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID

Retrieved on: 
Wednesday, October 12, 2022
Quality of life, U.S. Department of Defense Strategy for Operating in Cyberspace, Pancreatic cancer, PDAC, United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Communication, Therapy, SEC, Development, Human services, Diagnosis, EC50, Pneumonia, GMP, Severe acute respiratory syndrome coronavirus 2, COVID, DIPG, Patient, Brain, Research, Annual report, JV, Cancer, Private Securities Litigation Reform Act, BARDA, Form 10-K, Administration, Company, Department, Gilead, Adult, Optimism, Ageing, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Radiation, Fibrosis, GLOBE, Forward-looking statement, Breathe Me, COVID-19, OTCQB, Risk, Pharmaceutical industry, Dragon

The data will be used to design the next clinical trial aiming at demonstrating effectiveness of OT-101 against COVID-19 and long-term COVID-19.

Key Points: 
  • The data will be used to design the next clinical trial aiming at demonstrating effectiveness of OT-101 against COVID-19 and long-term COVID-19.
  • OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer.
  • It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
  • Forward-looking statements are based on expectations and assumptions as of the date of this press release.

Setting the Highest Standard: 2022 Heart of Case Management Awards

Retrieved on: 
Tuesday, October 11, 2022
Technology, Insurance, Hospitals, Telemedicine, Virtual Medicine, Professional Services, Health Insurance, Software, Practice Management, Health, Trust, Time, NP-hardness, Fatality, Kunde, Communication, ICU, Mitchell, Health status of Asian Americans, Hospital, Diagnosis, Survivor, United States Public Health Service, Cardiology, IME, COVID, Case management (US healthcare system), Family, Case management, SSDI, Brachial plexus, Income, Depression, Research, Burns, Workforce, Fortune 500, Technology, Knowledge, Social Security Disability Insurance, Goal, Tracheotomy, Social, Disability, Rhabdomyolysis, Intravenous therapy, Rehabilitation, Diabetes, Workplace, Amputation, Skin, Injury, Harrell, Cardiac arrest, Intubation, Breathe Me, Diathesis–stress model, Foot, Data analysis, Solution, Gangrene, Medicine, Health insurance, Insurance, Genex Power

This was the case for this years winners of Genexs Heart of Case Management Awards, who overcame overwhelming odds to help injured employees meet their recovery goals.

Key Points: 
  • This was the case for this years winners of Genexs Heart of Case Management Awards, who overcame overwhelming odds to help injured employees meet their recovery goals.
  • The Genex Heart of Case Management Award recognizes four case managers who have made the greatest impact on the injured employees they served.
  • Two other case managers helped a police officer and an employee overcome life-endangering COVID to reach their highest level of functioning.
  • The adjuster referred the case to Genex case management, specifically requesting Mary Meagan Campbell-Pittman due to her excellent reputation and ICU nursing background.

Experimental Treatment Approach Counters Allergic Asthma without Weakening Flu Defenses

Retrieved on: 
Friday, October 7, 2022
Tao, National Institutes of Health, Medical research, NYU, New York University Grossman School of Medicine, Novo Nordisk Foundation, Science Advances, National, Icahn School of Medicine at Mount Sinai, Lung, German Research Foundation, Pathology, Virus, Feces, Infection, Inflammation, Breathe Me, Mouse, Center, Department, Mount Sinai School, Korea Disease Control and Prevention Agency, Wang, Asthma, Child, Cough, Society, Calcium, Cell, ORAI1, American Society of Hematology, Allergen, Membrane protein, St. Jude Children's Research Hospital, Immunoglobulin E, NYU Langone Health, Wheeze, Acute pancreatitis, Eosinophil, Gene expression, Experimental pathology, Disease, CRAC, Cytokine, Pain scale, MD, Doctor of Philosophy, Bernard Levin, COVID-19, Vaccine, Pharmaceutical industry, Science, T helper cell, New York University

Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.

Key Points: 
  • Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.
  • Allergic asthma is characterized by increased type 2 (T2) inflammation, which involves a subset of T cells called T helper (Th) 2 cells, say the study authors.
  • Without calcium entering through CRAC channels, T cells are unable to become Th2 cells and produce the cytokines that cause allergic asthma, the authors say.
  • "This suggests CRAC channel inhibition as a promising, potential future treatment approach for allergic airway disease."

BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Retrieved on: 
Wednesday, October 5, 2022
Time-invariant system, D2, Atherosclerosis, Sepsis, United States Department of Health and Human Services, Breathe Me, Biomedical Advanced Research and Development Authority, Disease, Hospital, Sickle cell disease, Coagulation, Indapamide, Pandemic, Spironolactone, Development, Human services, Pulmonary hypertension, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Education, COVID, Allergic rhinitis, Medicine, Patient, Thrombosis, Open philanthropy (doctrine), Ogletree, Degenerative disease, Immune system, Administration, Company, PGD2, Health, Hypoxemia, Department, Blood, A2, Biolink zones, Eplerenone, Prostaglandin D2, Thromboxane A2, Philanthropy, COVID-19, Mouth, Silicosis, Pharmaceutical industry, Ramatroban

BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.

Key Points: 
  • BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.
  • Ramatroban has been approved and used in Japan for over 20 years for treatment of allergic rhinitis by twice daily oral administration.
  • BioLink Life Sciences is a North Carolina based clinical research company that develops novel, proprietary pharmaceutical products via multiple regulatory pathways.
  • KARE Biosciences is also developing a novel, antihypertensive combination of indapamide, the best-in-class thiazide-like diuretic, in combination with a mineralocorticoid receptor antagonist (spironolactone or eplerenone).

Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice

Retrieved on: 
Monday, October 3, 2022
General Health, Health, Other Health, Medical Devices, Regulation, Second Amendment to the United States Constitution, Achievement, Breathe Me, Hypercapnia, Regulation Fair Disclosure, Security, Compliance, Food, U.S. Securities and Exchange Commission, VAPO, Private Securities Litigation Reform Act, Hypoxemia, Patent, Failure, COVID-19, District of Columbia Voting Rights Amendment, Finance Secretary (India), Food and Drug Administration, Notice, Gas, LIBOR, NYSE, Plan, Security (finance), Patient, Risk, Investor relations, Term, Security agreement, Company, Vapotherm

In accordance with the NYSE rules, the Company intends to notify the NYSE within 10 business days of receipt of the Notice that the Company intends to cure the deficiency.

Key Points: 
  • In accordance with the NYSE rules, the Company intends to notify the NYSE within 10 business days of receipt of the Notice that the Company intends to cure the deficiency.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties, including its intent to regain compliance with the NYSE continued listing standards.

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

Retrieved on: 
Monday, October 3, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Migraine, New Drug Application, CGRP, CYP3A, PDUFA, Phonophobia, Myostatin, Pregnancy, Review, Disease, Hypersensitivity, Food, CYP3A4, Calcitonin, PFE, Inc., FDA, NDA, Internal medicine, Sound, Food and Drug Administration, Vomiting, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Headache, Lactation, Patient, Rash, Acquisition, Breathe Me, New, Nausea, KV7, Contraindication, Rimegepant, Pharmaceutical industry, Fine chemical, Aroma compound, Pfizer

As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer.

Key Points: 
  • As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer.
  • Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.s shares to Biohavens shareholders.
  • Biohaven Ltd., a new company that retained Biohavens non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition.
  • Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.s shares in the distribution and owns approximately 3% of Biohaven Ltd. Biohaven Ltd. will continue to trade on the New York Stock Exchange under the ticker BHVN.

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Retrieved on: 
Thursday, September 29, 2022
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, Safety, Autoantibody, Diabetes, Inflammatory bowel disease, Health, Pressure, Patient, Hair, Clinical trial, Nasdaq, Research, Menstrual disorder, Inflammation, Disease, Headache, Diplopia, CAS, Exophthalmos, Lists of World Heritage Sites, COVID-19, Blood pressure, Food, Tachycardia, Diarrhea, Orbital, Hyperglycemia, Pain, Grit, Science, Adult, Autoimmunity, Medicine, Nausea, SEC, Courage, Fibroblast, European Group, FDA, Graves' ophthalmopathy, Week, Partnership, TED, Instagram, Cedars-Sinai Medical Center, Fatigue, Incidence, Huber loss, Twitter, Spasm, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cell, Red, Clinical, IBD, Myalgia, Swelling, Breathe Me, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Birth control, Dysgeusia, Facebook

Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.
  • TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first and only medicine for Thyroid Eye Disease.
  • The TEPEZZA pivotal trial data showed significant improvement in some of the most debilitating symptoms of TED in people with more inflammatory disease.
  • We frequently hear people with Thyroid Eye Disease stress how the painful, potentially vision-threatening symptoms continue throughout the patient journey.